Previous Close | 0.0300 |
Open | 0.0300 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 55.00 |
Expire Date | 2024-06-14 |
Day's Range | 0.0300 - 0.0300 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.
The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to expand access to immuno-oncology therapy Opdivo™ in select countries PRINCETON, NJ / ACCESSWIRE / May 22, 2024 /Bristol Myers Squibb (NYSE:BMY) ...